Novavax ( (NVAX) ) has released its Q3 earnings. Here is a breakdown of the information Novavax presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Novavax, Inc. is a biotechnology company specializing in the development of vaccines using its proprietary technology platform, including protein-based nanoparticles and the Matrix-M adjuvant, aimed at addressing global health challenges. In its third-quarter 2025 earnings report, Novavax reported a total revenue of $70 million, marking a decrease from the previous year, while highlighting key strategic partnerships and advancements in its vaccine pipeline. The company has successfully executed its partnership with Sanofi, achieving $225 million in milestones year-to-date, and has seen positive developments in its Nuvaxovid vaccine in combination with flu vaccines. Novavax also reported significant cost savings from consolidating its Maryland facilities and has raised its full-year 2025 revenue framework. Despite a net loss of $202 million for the quarter, the company continues to focus on R&D and partnerships to drive long-term growth and profitability. Looking ahead, Novavax remains committed to leveraging its technology platform and strategic collaborations to enhance its market position and financial performance.